Harvard/NIH: Cannabis Derivative and Pancreatic Cancer Potential

Harvard/NIH: Cannabis Derivative and Pancreatic Cancer Potential, July 2019

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663976/

Abstract: This study reports on a new non-cannabinoid, non-psychoactive derivative of cannabis, termed FBL-03G, with the potential to treat pancreatic cancer. In vivo results demonstrate therapeutic efficacy in delaying both local and metastatic tumor progression in animal models with pancreatic cancer when using FBL-03G sustainably delivered from smart radiotherapy biomaterials. Repeated experiments also showed significant (P < 0.0001) increase in survival for animals with pancreatic cancer compared to control cohorts. The findings demonstrate the potential for this new cannabis derivative in the treatment of both localized and advanced pancreatic cancer, providing impetus for further studies toward clinical translation.

“The most significant conclusion is that tumor-targeted delivery of flavonoids, derived from cannabis, enabled both local and metastatic tumor cell kill, significantly increasing survival from pancreatic cancer,” Ngwa tells Yahoo Lifestyle. “This has major significance, given that pancreatic cancer is particularly refractory to current therapies.”